NEW YORK, March 20 – Toronto-based MDS Proteomics said Tuesday it has opened a new facility in Odense, Denmark and is in the process of building new facilities in Boston and Charlottesville, NC.
The facility in Odense employs more than 60 scientists and has a number of customized mass spectrometers as well as one of the largest Linux clusters, with 101 computers that each have 2 x 1 Ghz CPU and 2 GB ram, the company said.
"MDS Proteomics recognizes that by increasing our geographic footprint, we can continue to attract the most talented scientists located in major biotechnology centers worldwide,” Frank Gleeson, MDS Proteomics’ CEO, said in a statement.
The company, a subsidiary of MDS, is also expanding its Toronto facility, where it analyzes protein interaction pathways and produces data for its proprietary BIND database, which is used to select and validate targets for its customers.
Earlier this year IBM invested $10 million in MDS Proteomics as part of a strategic collaboration that also included an agreement to jointly establish BIND, a publicly available web-based protein database based in Toronto.
At the Boston facility, scientists will focus on high throughput screening, structural biology and drug design, medicinal chemistry, and protein identification. And, the Charlottesville complex will specialize in the analysis of complex mixtures of proteins to identify novel membrane bound receptor proteins as targets for therapeutic drugs.